As of November 6, 2026, Cytek Biosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 2, 2026 to June 25, 2026 (Form 8-K, June 25, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cytek Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cytek Biosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-02 to 2026-06-25. Every row below is cited to the filing it comes from, and this page adds each new change as Cytek Biosciences, Inc. files it.
Also on the record for Cytek Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 5.6% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 7.2% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by Boston Partners | 5.91% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.2% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 6.1% of the class | 5%+ stakes | Source |
| April 9, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.2% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 17, 2025 | Stake report, Schedule 13G, by Topline Capital Management, LLC | 5.3% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Brown Capital Management, LLC | 3.9% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 6.13% of the class | 5%+ stakes | Source |
| July 18, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 13.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cytek Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cytek Biosciences, Inc. and the records around it.
Cytek Biosciences, Inc. elsewhere on the record
Companies that share a holder
- Brown Capital Management, LLC also filed stake reports on 4 other companies: Cryoport Inc. (Feb 2026), OrthoPediatrics Corp. (Nov 2025)
- Topline Capital Management, LLC also filed stake reports on 13 other companies: AMERICAN VANGUARD CORP (Feb 2026), GREEN DOT CORP (Feb 2026), KORU Medical Systems, Inc. (Feb 2026)
- Boston Partners also filed stake reports on 28 other companies: CROSS COUNTRY HEALTHCARE INC (Nov 2026), DoubleDown Interactive Co., Ltd. (Nov 2026), Holley Inc. (Aug 2026)
Watch Cytek Biosciences, Inc.
Get an email when Cytek Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cytek Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cytek Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cytek Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-25 | Reported | not named in the filing | 8-K, 2026-06-25 | ||
| 2026-06-02 | Reported | not named in the filing | 8-K, 2026-06-02 |
New leaders reset buying decisions — get the Full Report on Cytek Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Cytek Biosciences, Inc., with the record behind each one.
Find candidates like senior executive at Cytek Biosciences, Inc.Every change, in the filing's words
Reported
(b) On June 18, 2026, Valerie Barnett and Cytek Biosciences, Inc. (the "Company") agreed that Ms. Barnett's position as Chief Legal Officer and Corporate Secretary of the Company would terminate effective as of June 29, 2026.
- Ms. Barnett's separation is not due to any disagreement with the Company's operations, policies or practices.
Reported
Dr. Busque's resignation is not due to any disagreement with the Company's operations, policies or practices.
- On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the "Company"), effective as of June 5, 2026, to pursue another career opportunity.
Tools for this story
Each opens in a new tab, filled in for Cytek Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.